Eli Lilly is rapidly growing its obesity and diabetes treatment portfolio, with its tirzepatide-based drugs Mounjaro and Zepbound generating nearly $15 billion in revenue and showing strong year-over-year growth of 91% and 46%, respectively. This growth supports a buy rating for Eli Lilly, justified by over 20% annual sales growth and strong free cash flow. The company’s robust balance sheet, capital allocation flexibility, and ongoing innovation underpin its premium valuation despite industry risks. Additionally, Eli Lilly recently received approval for a $3 billion facility in Katwijk, The Netherlands, signaling further expansion.
Eli Lilly's strong growth in obesity and diabetes treatments highlights its expanding role in healthcare innovation. On Pluang, Eli Lilly (LLY) trades at USD 1,184.00 with a positive 1-day change of 2.29% as of Oct 07, 2026 21:01 WIB. The stock holds a market cap of $1.03 trillion and a dividend yield of 0.6%, with typical investors holding for about 93 days and a balanced order activity leaning slightly towards selling at 55%.
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
Eli Lilly (LLY) is recommended as a Strong Buy due to its attractive valuation and role as a diversification play for portfolios heavily invested in AI. Trading at about 24 times its 2027 earnings estimates, the stock is seen as premium but not overp...
Eli Lilly's stock is predicted to rise nearly 19% over the next year, driven by rapid growth in its oncology, immunology, and neuroscience drug portfolios, which grew 121% year-over-year last quarter. While known for weight loss drugs like Mounjaro a...
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
